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BACKGROUND AND PURPOSE
The non-selective sodium channel inhibitor mexiletine has been found to be effective in several animal models of chronic pain
and has become popular in the clinical setting as an orally available alternative to lidocaine. It remains unclear why patients
with monogenic pain disorders secondary to gain-of-function SCN9a mutations benefit from a low systemic concentration of
mexiletine, which does not usually induce adverse neurological side effects. The aim of this study was, therefore, to
investigate the biophysical effects of mexiletine on the L858F primary erythromelalgia NaV1.7 mutation in vitro.
EXPERIMENTAL APPROACH
Human wild-type and L858F-mutated NaV1.7 channels were expressed in HEK293A cells. Whole-cell currents were recorded
by voltage-clamp techniques to characterize the effect of mexiletine on channel gating properties.
KEY RESULTS
While the concentration-dependent tonic block of peak currents by mexiletine was similar in wild-type and L858F channels,
phasic block was more pronounced in cells transfected with the L858F mutation. Moreover, mexiletine substantially shifted
the pathologically-hyperpolarized voltage-dependence of steady-state activation in L858F-mutated channels towards wild-type
values and the voltage-dependence of steady-state fast inactivation was shifted to more hyperpolarized potentials, leading to
an overall reduction in window currents.
CONCLUSION AND IMPLICATIONS
Mexiletine has a normalizing effect on the pathological gating properties of the L858F gain-of-function mutation in NaV1.7,
which, in part, might explain the beneficial effects of systemic treatment with mexiletine in patients with gain-of-function
sodium channel disorders.
Abbreviations
A/D, analogue to digital; Erev, reversal potential; I, current; NaV, voltage-gated sodium channel; PEM, primary
erythromelalgia; WT, wild type
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Table of Links
TARGETS LIGANDS
NaV Mexiletine
NaV1.7 Lidocaine
This Table lists key protein targets and ligands in this document, which are hyperlinked to corresponding entries in http://
www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and
are permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (Alexander et al., 2013).
Introduction
The non-selective sodium channel inhibitor mexiletine
hydrochloride [1-methyl-2-(2,6-xylyloxy)ethylamine hydro-
chloride] has been extensively studied and used clinically for
decades because of its antiarrhythmic effects (Chew et al.,
1979; Woosley et al., 1984; Fenster and Comess, 1986; Monk
and Brogden, 1990). More recently, it has also been found to
be effective in several animal models of chronic pain and it
has been suggested as a third-line treatment instead of sys-
temic lidocaine for neuropathic pain syndromes (Jarvis and
Coukell, 1998; Kuhnert et al., 1999; Mao and Chen, 2000;
Challapalli et al., 2005; Tremont-Lukats et al., 2005; Ebell,
2006; Marmura, 2010). Based on its almost complete absorp-
tion after oral administration, its low first-pass effect and a
plasma elimination half-life of approximately 10–14 h, it is
also an orally available alternative to lidocaine for systemic
treatment (Middleton, 1980).
Recently, it has been noted that systemic treatment with
mexiletine alleviates the symptoms and signs of myotonia
in non-dystrophic myotonia (Statland et al., 2012). Non-
dystrophic myotonia results from mutations in the voltage-
gated sodium channel encoded by the gene SCN4A
(Matthews et al., 2010). In comparison, gain-of-function
mutations in the related SCN9A gene, which encodes NaV1.7,
can result in primary erythromelalgia (PEM), either a familial
or a sporadic chronic neuropathic pain syndrome (Dib-Hajj
et al., 2005). Several publications have reported an analgesic
effect of mexiletine in patients suffering from this monogenic
pain disorder (Kuhnert et al., 1999; Legroux-Crespel et al.,
2003; Dib-Hajj et al., 2005; Nathan et al., 2005; Choi et al.,
2009). The apparent absence of pro-arrhythmic and other
major adverse effects at analgesic doses of mexiletine points
to a mode of action that preferentially affects pathological
channels. While a pronounced use-dependent sodium
channel block in an erythromelalgia-causing NaV1.7 muta-
tion has been demonstrated before (Choi et al., 2009), the
mechanisms that lead to the observed analgesic effect are not
fully understood. The L858F mutation in NaV1.7 is one of the
best characterized and most common gain-of-function muta-
tions that leads to PEM and is associated with a severe phe-
notype (Han et al., 2007; Samuels et al., 2008; Cheng et al.,
2011; Segerdahl et al., 2012). The 858 residue is located near
the pore region within the second domain of NaV1.7
(Figure 1A). Sequence alignment of voltage-gated sodium
Figure 1
(A) Diagram of NaV1.7 showing the location of the p.L858F amino
acid substitution. p.L858F maps to the S4–S5 intracellular linker of
domain 2 and is identified by the orange solid circle and the arrow.
(B) Amino acid residue alignment around p.L858F. Amino acid
residue alignment demonstrating the magnitude of inter-isoform
and inter-species conservation of the affected regions. Orange resi-
dues identify the mutant p.L858F mapping to the S4–S5 linker of DII
of the human NaV1.7α subunit. Green colour indicates the corre-
sponding non-mutated variant.
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channels (NaVs) shows that the leucine at position 858 is
individually conserved in every member of the NaV family in
humans and highly evolutionarily conserved in all NaV1.7
homologues (Figure 1B). It has previously been shown that
the L858F mutation causes a hyperpolarizing shift in the
voltage- dependence of steady-state fast activation and an
enhanced response to slow depolarizations (Han et al., 2006).
Therefore, the aim of this study was to investigate the
biophysical effects of mexiletine on the PEM-causing L858F
NaV1.7 mutation in vitro, with particular focus on channel
gating properties. A better understanding of how mexiletine
affects the gating properties of a pathologically dysfunctional
channel may enable research to focus on specific gating prop-
erties of this channel for future drug development. Thus, we
expressed human NaV1.7 channels with or without the L858F
mutation in HEK293A cells and analysed the effect of mexi-
letine on their whole-cell voltage-clamp properties.
Methods
Plasmid and site-directed mutagenesis
A previously described full-length human SCN9A cDNA
sequence cloned into a modified pcDNA3 expression vector
containing downstream polio IRES and DsRED2 sequences
(FLRED) was used (Cox et al., 2006). The L858F mutation was
introduced into FLRED using the QuikChange II XL Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA)
according to the manufacturer’s instructions. The coding
sequence of both constructs was fully sequenced to verify the
desired mutation and to ensure that no other variations had
been introduced.
Cell culture and transfection
HEK293A cells were cultured in a humidified atmosphere
containing 5% carbon dioxide at 37°C and were grown in
DMEM (Gibco, Life Technologies, Carlsbad, CA, USA) supple-
mented with 10% heat-inactivated FBS. Unless stated other-
wise, reagents were purchased from Sigma Aldrich (St. Louis,
MO, USA).
Cells were transiently transfected with plasmid DNA for
expression of NaV1.7 human wild-type (WT) α subunits (Ref
Seq NM_002977) or L858F-mutated α subunits (SCN9A-IRES-
DsRed2 in pcDNA3 vector) combined with human WT β1
(Ref Seq NM_001037) and β2 (Ref Seq NM_001037) subunits
(SCN1B-IRES-SCN2B-IRES-eGFP in a pIRES2-AcGFP1 back-
bone vector) as previously described (Cox et al., 2006). In
brief, transient transfection was performed with cells seeded
at 80–90% confluency in 35 mm cell culture dishes using
Lipofectamine 2000 (Invitrogen, Life Technologies) according
to the manufacturer’s recommendations. After 6 h, the trans-
fection medium was replaced with fresh culture medium and
the cells re-seeded for electrophysiological recordings at
20–30% confluency.
Electrophysiological recordings
Whole-cell membrane current recordings were performed
46–78 h after transfection. All recordings were made at room
temperature. Micropipettes were pulled from borosilicate
glass capillaries (GC150F-10; Harvard Apparatus, Kent, UK)
using a Brown-Flaming P-97 horizontal micropipette puller
(Sutter Instruments, Novato, CA, USA, USA) and then fire
polished on a microforge (MF-830 Narishige Group, Tokyo,
Japan). Voltage errors were minimized with correction and
prediction mode of series resistance compensation, both set
to 50%. Extracellular (bath) solution contained (in mmol·L−1):
140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, adjusted to
pH 7.4 with NaOH, osmolarity 320–325 mOsm·L−1 with
glucose. Pipettes were filled with an intracellular solution
containing (in mmol·L−1): 140 CsCl, 5 NaCl, 5 EGTA, 2 MgCl2,
10 HEPES adjusted to pH 7.3 with CsOH, osmolarity 305–
310 mOsm·L−1 with glucose. Once filled with the appropriate
intracellular solution, recording electrodes had a resistance
between 2.0 and 3.2 MΩ. A silver chloride-coated silver wire
served as a reference electrode with one end connected to the
ground input of the amplifier and the tip placed directly into
the bath solution. Cells having a leak current, after establish-
ment of a whole-cell configuration, of more than 10% of the
peak sodium current were discarded and those which had
developed a leak current of this magnitude during the experi-
ment were not used in the final analysis. The liquid junction
potentials between the bath and the pipette solutions were
not corrected. Whole-cell membrane currents were filtered at
5 kHz and sampled at 20 kHz using an Axopatch 200B patch
clamp amplifier (Molecular Devices, Foster City, CA, USA)
and Digidata 1200B A/D (analogue to digital) converter
(Molecular Devices). Data were acquired on a Windows-based
PC using Clampex (Molecular Devices) software and analysed
by pCLAMP (Clampfit) 9.2 software (Molecular Devices).
Mexiletine treatment
Mexiletine hydrochloride salt was dissolved in extracellular
(bath) solution to give a stock solution of 100 mM and pH
was adjusted to 7.4. Subsequent dilutions were performed in
a standard external solution to reach the desired concentra-
tions. Addition of mexiletine did not change the osmolarity
of the extracellular solution used in these experiments. For
microperfusion with laminar flow at 1 mL·min−1, a gravity-
driven perfusion system (MEV-9, BioLogic Science Instru-
ments, Claix, France) equipped with polyethylene tubing was
used. The solution was removed using a Dymax 5 suctioning
apparatus (Charles Austen Pumps Ltd., Byfleet, Surrey, UK).
For concentration–response experiments, mexiletine was
applied in a stepwise approach from the lowest to highest
concentration, and 30 s was allowed after each concentration
change for the response to reach a plateau before the effect
induced was recorded.
Voltage-clamp protocols
To characterize the voltage-dependence of the steady-state
channel activation, currents were evoked by voltage incre-
ments of 10 mV from −80 to +40 mV for 10 ms from a
holding potential of −120 mV with 5 s between pulses. Con-
ductance (G) values were calculated from the peak inward
currents (I) measured and the reversal potential for sodium
ions (Erev Na) observed using the equation G = I/(Vm − Erev Na).
Reversal potential was measured by extrapolating the
linear portion of the I/V relationship between +10 and
+40 mV. The resulting values for conductance were normal-
ized to the peak conductance and fitted using the Boltzmann
equation. Steady-state inactivation of WT NaV1.7 channels or
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L858F mutant channels was assessed by holding cells at
increasing potentials from −110 to 0 mV for 500 ms, followed
by a step to −10 mV for 50 ms.
For characterization of the use-dependence of mexiletine-
induced block in NaV1.7 WT and L858F variant channels,
currents were elicited in whole-cell configuration by initially
holding the cell at −120 mV and stepping up to 0 mV for
5 ms every 200 ms, generating pulses at a frequency of 5 Hz.
Statistical analysis
All data are expressed as means ± SEM. Differences in means
between WT channels and mutations were tested by Stu-
dent’s two-tailed t-test or one-way ANOVA with the Bonferroni
post test where appropriate. P < 0.05 was considered signifi-
cant. Calculations were made using the GraphPad Prism soft-
ware version 5.0 (GraphPad Software Inc., La Jolla, CA, USA).
Results
HEK293A cells transfected with the NaV1.7 α subunit contain-
ing the L858F mutation (n = 35) in combination with the
NaVβ1 and NaVβ2 subunits did not differ significantly from
cells with WT NaV 1.7 (n = 29) in terms of peak current
densities and whole-cell capacity and series resistance
(Table 1). The inhibition of WT and L858F channels by mexi-
letine was assessed by measuring the magnitude of the reduc-
tion in peak current achieved by depolarizing cells to 0 mV
from a resting potential of −120 mV. Both peak currents (WT
and L858F) were reduced in the presence of mexiletine in a
concentration-dependent manner (Figure 2A). The fit of
concentration–response curves with a first-order binding
function revealed that the half-maximal blocking concentra-
tion (IC50) was 1.1 ± 0.05 mM for the WT and 0.87 ± 0.06 mM
for the L858F mutant channels.
Channels with the L858F mutations demonstrated a
greater amount of use-dependent normalized peak current
fall-off when compared with the WT in the presence of mexi-
letine (500 μM) when depolarized at a frequency of 5 Hz
(Figure 2B and C). Comparing averaged currents recorded
between pulse 10 and 20 with currents recorded between
pulse 140 and 150, normalized peak current for cells express-
ing channels with the L858F mutation were reduced by 26%
(n = 8; P < 0.05), while the effect of mexiletine on currents
recorded fromWT controls remained unchanged (Figure 2D).
In NaV1.7 channels with the L858F mutation, the voltage-
dependence of channel activation was found to be changed
to more hyperpolarizing potentials compared with WT chan-
nels when normalized peak inward currents were plotted as a
function of depolarization potential to demonstrate the
current–voltage relationship (Figure 3A and B). When the
resulting conductance values were fitted to a Boltzmann
equation (Figure 3C), the L858F mutation caused a hyperpo-
larizing shift in the voltage-dependence of steady-state acti-
vation (Figure 3D; P < 0.01), with a voltage step leading to
half-maximal activation (V1/2act) of −19.7 ± 1.3 mV (n = 20)
compared with −2.6 ± 1.3 mV (n = 15) in WT controls (P <
0.01). While mexiletine (500 μM) did not have an effect on
the voltage-dependence of steady-state activation in WT
NaV1.7 channels (−5.0 ± 2.7 mV; n = 9), it shifted those of
channels with the L858F mutation towards physiological
values (−4.5 ± 3.3 mV) (Figure 3D; n = 20; P < 0.01). Further-
more, in L858F mutant channels, the slope of the function
describing the voltage–conductance relationship was signifi-
cantly changed by mexiletine (4.6 ± 0.7 vs. 8.5 ± 1.2; P <
0.001; Figure 3C), whereas it remained unchanged in NaV1.7
WT channels (5.1 ± 0.2 vs. 5.4 ± 0.4).
When analysing the voltage-dependence of the steady-
state fast inactivation (Figure 4), we found no difference in
the voltages with half-maximal inactivation (V1/2inact) between
WT channels and those with the L858F mutation (−59.3 ±
3.1 and −56.5 ± 2.5 mV respectively). Mexiletine (500 μM)
shifted the V1/2inact towards more hyperpolarized potentials for
NaV1.7 WT and L858F mutant channels (−77.3 ± 4.7 mV; n =
14; P < 0.01 and −73.0 ± 2.2 mV; n = 15; P < 0.01 respectively).
The slope factors of fitted curves did not differ between L858F
mutants and WT NaV1.7.
A composite graph showing Boltzmann fits of mean acti-
vation and steady-state inactivation curves of L858F mutant
versus WT channels showed an increase in the window
current (Figure 5). Maximum window currents for WT NaV1.7
channels were 4.5% of the peak currents (AUC = 0.82) as
opposed to 11.5% seen in the mutant channel population of
cells (AUC = 2.49). Following the application of mexiletine
(500 μM) and after a steady state had been reached, there was
a reduction in the maximum window current to 5.5% of peak
currents in L858F channels and a reduction in the window
current AUC by 48% (AUC = 1.29).
Discussion
PEM is a devastating human disorder in which patients suffer
from excruciating episodic pain, mainly in the hands and
feet. A frequently used treatment for this disorder is the
sodium channel blocker mexiletine. Here, we have studied
the concentration- and frequency-dependent effects of
mexiletine on NaV1.7 channels with the erythromelalgia-
associated mutation L858F, whose effect on channel proper-
ties as has been described previously (Han et al., 2007; Cheng
et al., 2011). Intriguingly, mexiletine caused a change in the
gating properties of this mutated channel, leading to an
almost completely normalized voltage-dependence of activa-
tion and window currents, whereas the voltage-dependence
Table 1
Cell and recording properties
Peak
current
(nA)
Whole-cell
capacity
(pF)
Series
resistance
(MΩ)
Controls (n = 29) −0.68 (0.09) 16.8 (1.88) 12.7 (1.22)
L858F (n = 35) −0.53 (0.08) 22.7 (1.90) 16.4 (1.99)
P value 0.08 (ns) 0.12 (ns) 0.11 (ns)
Data presented as mean values and SEM. Differences in means
of cells with NaV1.7 L858F mutant channels compared with
NaV1.7 wild-type controls were tested by Student’s two-tailed
t-test. P < 0.05 was considered significant.
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of the steady-state fast inactivation was shifted to more
hyperpolarized potentials in both the WT and mutant L858F
channels to a similar degree. This effect substantially contrib-
uted to the reduction in the windows currents observed after
treatment with mexiletine in L858F mutant channels.
Although the effects of mexiletine have been investigated
previously in another (V872G) NaV1.7 mutation in vitro,
where it was shown to induce use-dependent current block-
ing effects (Choi et al., 2009), to our knowledge, this is the
first evidence that the mechanism of action of mexiletine on
erythromelalgia channel mutations involves an effect on
their gating properties.
Furthermore, we observed that mexiletine induced a use-
dependent inhibition of peak currents in the L858F mutant
channels. A likely explanation for this phenomenon has been
suggested by Waxman and co-workers (Choi et al., 2009)
when investigating another mutant channel. V872G was
tested in similar conditions with high-frequency stimulation
pulsing to −10 mV in the presence and absence of mexiletine.
A stronger, use-dependent fall-off of current can be explained
by a hyperpolarizing shift in activation of the mutant
channel. Thus, a greater proportion of mutant channels will
be opened and then inactivated during the early part of
action potential generation. Once reaching +20 mV,
Figure 2
Concentration-dependent and use-dependent effects of mexiletine on NaV1.7-mediated currents in HEK293 in whole-cell voltage-clamp con-
figuration. (A) Concentration-dependent reduction in peak current by mexiletine in wild-type NaV1.7 control channels and L858F channel
mutation. Non-linear regression, calculated by plotting log-transformed inhibitor versus normalized response, generated IC50 of 1.1 mM (0.05)
for wild-type NaV1.7 channels and 0.87 mM (0.06) for L858F mutant channels. (B) Representative examples of current traces before and during
treatment with mexiletine (500 M) at the last depolarizing voltage step of a high-frequency stimulation protocol with 150 pulses at 5 Hz as
described below. (C/D) Peak currents were normalized to maximum currents in untreated controls. Currents were elicited in whole-cell
configuration by initially holding the cell at −120 mV and stepping up to 0 mV for 5 ms every 200 ms, generating pulses at a frequency of 5 Hz.
While mexiletine (500 μM) led to a use-dependent fall-off in peak current for L858F, no use-dependent effect was found in controls with wild-type
NaV1.7 channels. All data are presented as means ± SEM (n = 8). One-way ANOVA and post hoc Bonferroni test; *P < 0.05.
BJPEffect of mexiletine on L858F NaV1.7 channels
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activation of both V872G as well as WT channels is at its
maximum. At −10 mV, however, it is possible for us to
observe this effect. When comparing the use-dependent
effect to tonic block, we also think that a frequency-
dependent interaction between L858F and mexiletine may be
the main reason why this drug, as well as other sodium
channel blockers, is effective in PEM.
In a recent study of a gain-of-function mutation (M1476I)
in NaV1.4 (Zhao et al., 2012), which is associated with cold-
induced myotonia, effects on channel gating properties were
also observed, although mexiletine significantly shifted the
voltage-dependent activation and inactivation curves of both
WT and M1476I channels in a hyperpolarizing direction. In
contrast, the voltage-dependence of activation in NaV1.7
L858F channels was shifted in a depolarizing direction,
whereas wild-type channels remained unaffected. In agree-
ment with their findings, we found a hyperpolarizing shift in
steady-state fast inactivation. Subtype-specific effects on
voltage-gating properties of NaV have been found before, for
example, for lidocaine (Chevrier et al., 2004), which only
Figure 3
Voltage-dependence of steady-state activation of NaV1.7-mediated currents in whole-cell voltage-clamp configuration. (A) Representative current
traces recorded from HEK293A cells that expressed wild-type (left) or L858F mutant (right) NaV1.7 together with hβ1 and hβ2. Whole-cell Na+
currents were elicited by 10 ms test pulses with 5 s intervals to potentials between −80 and 40 mV in steps of 10 mV from a holding potential of
−120 mV. (B) Current–voltage plot of wild-type NaV1.7 (Controls), wild-type NaV1.7 channels exposed to 500 μM mexiletine (Controls + Mex),
L858F mutation (L858F) and L858F mutation exposed to 500 μMmexiletine (L858F + Mex). (C) Conductance values from HEK293 cells expressing
wild-type Nav1.7 (Controls), wild-type NaV1.7 channels exposed to 500 μM mexiletine (Controls + Mex), L858F mutants (L858F) and L858F
mutants exposed to 500 μM mexiletine (were calculated from peak inward currents in activation protocols, normalized and fitted using the
Boltzmann equation). (D) Analysis of voltages for half-maximal activation (V1/2act) revealed a hyperpolarizing shift in the voltage-dependence of
steady-state activation in L858F-expressing cells compared with controls. Mexiletine treatment of L858F-expressing cells, however, shifted the
current-voltage relationship towards wild-type values, although a complete return to physiological values was not achieved. Please note that the
mean data as used for statistical analysis do not entirely correspond to the graph depicted in panel (B) as these were fitted from averaged
experimental results to demonstrate one representative graph for display purposes. All data presented are as means ± SEM; n = 20 for controls;
n = 9 for controls exposed to mexiletine, n = 15 for L858F mutation and n = 20 for L858F mutation exposed to mexiletine. One-way ANOVA with
post hoc Bonferroni test; ***P < 0.001.
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shifts steady-state inactivation, but not activation in NaV1.7,
while both activation and inactivation were affected in
NaV1.8.
It should be noted that the concentration of mexiletine
found to be effective in the experiments described is much
higher than expected, based on the therapeutic concentra-
tions active clinically. This may, in part, be explained by the
simplified nature of the experiments, with cells highly over-
expressing the investigated channel, acute wash-in of mexi-
letine rather than the slow accumulation that would in
neuronal tissues in vivo, and the experiments were performed
at lower ambient temperatures. A further reason may be
related to the use-dependence of the drug, since in our experi-
ments the membrane was held at a potential of −120 mV to
remove steady-state inactivation. This may have resulted in a
reduction in the blocking potency due to the unavailability of
channels that would normally be open at the resting mem-
brane potential of nociceptive neurons. Indeed, a reduction
in the blocking potency of the same drug has already been
described for voltage-gated sodium channels in skeletal
muscle (Courtney, 1981). Nevertheless, the higher IC50 values
for the channel blocking actions of sodium channel blockers
observed is very common for this type of experimental
approach, as recently demonstrated for lidocaine (Sheets
et al., 2011).
Other medications that have been demonstrated to be of
benefit in erythromelalgia patients have been previously
investigated in vitro and responsiveness to treatment has been
shown to be dependent on the exact causative mutation. For
example, carbamazepine has been shown to normalize the
hyperpolarizing shift in the voltage-dependence of activation
produced by the V400M or S241T NaV1.7 mutations but have
no effect on the F1449V mutation (Fischer et al., 2009; Yang
et al., 2012). Similar effects on the voltage-dependence of
steady-state fast inactivation have been observed previously
for carbamazepine, phenytoin and lamotrigine in WT
Figure 4
Voltage-dependence of steady-state fast inactivation of NaV1.7-
mediated currents in whole-cell voltage-clamp configuration. (A)
Voltage-dependent inactivation in HEK293 cells expressing wild-
typeNaV1.7 (Controls), wild-type NaV1.7 channels exposed to
500 μM mexiletine (Controls + Mex), L858F mutants (L858F) and
L858F mutants exposed to 500 μM mexiletine (L858F + Mex) was
assessed by holding the cells at potentials increasing from −120 to
0 mV for 500 ms, followed by a step to −10 mV for 50 ms, normal-
ized to peak currents and fitted using the Boltzmann equation. (B)
Analysis of voltages for half-maximal inactivation (V1/2inact) in L858F-
expressing cells and wild-type NaV1.7 controls. A similar degree of
hyperpolarizing shift in inactivation curves was observed in L858F
mutant- and the wild-type NaV1.7-expressing cells exposed to
500 μM mexiletine. Slope factors of the fitted curves did not differ
between L858F mutants and wild-type NaV1.7. All data are presented
as means ± SEM; n = 7 for controls; n = 5 for controls exposed to
mexiletine, n = 19 for L858F mutation and n = 12 for L858F mutation
exposed to mexiletine. One-way ANOVA with post hoc Bonferroni test;
*P < 0.05; ***P < 0.001.
Figure 5
Analysis of window currents in whole-cell voltage-clamp configura-
tion of NaV1.7-expressing HEK293 cells. Combined superimposed
fitted curves of steady-state activation and fast inactivation kinetics in
cells expressing NaV1.7 channels (controls or L858F mutant) with
NaVβ1 and NaVβ2 subunits. Window currents of cell population
expressing wild-type channels (green striped area) were reduced by
mexiletine (500 μM; green solid area). Mexiletine treatment
(500 μM; red solid area) also reduced window currents of cells
expressing L858F mutant channels (red striped area). All data are
presented are as means.
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voltage-gated sodium channels in rat cultured cortical
neurons (Errington et al., 2008).
A further example of a substance with effects on voltage-
gating properties of wild-type NaV1.7 is the sea anemone
peptide blood-depressing substance I (BDS-I), which was
found to shift the voltage-dependence of both activation
and inactivation towards more depolarized potentials. Fur-
thermore, the authors also reported a change in the slope
factor of the activation curve, an effect that we also
observed for mexiletine in the L858F mutant channels (Liu
et al., 2012).
More recently, Wu and colleagues characterized three
patients clinically diagnosed and confirmed to host
EM-causative mutations in their SCN9A genes. Causative
mutations were overexpressed in CHO cells, and IC50 values
of lidocaine and mexiletine were compared with the muta-
tions identified as I136V, I848T and V1316A (Wu et al., 2013).
They found differential effects between lidocaine and mexi-
letine, which were similar to the treatment effects observed in
the affected patients.
Despite the almost complete normalization of activation
properties in our case and tendency to normalization of
repetitive firing current characteristics, a complete diminish-
ment of the phenotypic aberrations affecting the sufferers of
this rare but extremely debilitating painful disorder has not
yet been reported. As recently proposed (Estacion et al., 2011;
Waxman, 2013), PEM symptoms might result from interac-
tions between sympathetic and sensory neurons and so treat-
ment modalities focused on altering neuronal excitability in
the dorsal root ganglia alone may be either ineffective or only
partially beneficial. Although mexiletine can provide some
pain relief for erythromelalgia patients, it is by no means a
cure for all. By understanding how mexiletine alters the bio-
physical properties of specific mutant NaV1.7 channels, such
as the one investigated in this study, we can potentially find
new and better ways to normalize these biophysical proper-
ties and hopefully ameliorate pain.
Conclusions
In summary, our study demonstrates an example of predict-
ing the treatment effect of mexiletine in patients suffering
from a specific gain-of-function mutation in NaV1.7. By
applying the same in vitro approach to other PEM mutations,
it might be possible to provide an informed prediction of the
usefulness of mexiletine as a treatment for this rare inherited
pain disorder.
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